



State CHEST Conference

YaleCME
CONTINUING MEDICAL EDUCATION

Presented by

Yale School of Medicine's Department of Internal Medicine - Section of Pulmonary, Critical Care & Sleep Medicine

Year in Review Cystic Fibrosis



Jon Koff, MD

Associate Professor of Medicine, Pulmonary
Director, Adult Cystic Fibrosis Program
Yale School of Medicine



Gail L Stanley, MD, MPH

Clinical Fellow of Medicine
Pulmonary, critical Care and Sleep Medicine
Yale School of Medicine

Wednesday, February 19, 2020, 3-4 pm

Fitkin Amphitheatre

Moderator: Clemente Britto-Leon, MD

There is no corporate support for this activity

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

NEEDS ASSESSMENT

Cystic fibrosis (CF) is a multisystem disease that is characterized by chronic sinusitis, obstructive lung disease, pancreatic insufficiency, chronic constipation, CF-related diabetes, and CF-related liver disease that contribute to a significantly reduced life span. CF patient outcomes have improved over the past 20 years because of center-based care, improved nutrition, airway clearance therapies, new anti-infectives, and the more recent introduction of modulators that modify specific CF mutations, which represents a new era in personalized medicine for CF. Despite this progress, individuals with CF continue to suffer from chronic lung inflammation and bronchiectasis that cause recurrent pulmonary exacerbations, which are complicated by increasingly drug resistant pathogens. Therefore, there remains a significant need for novel anti-inflammatory and anti-infective treatments.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will learn to:

- I. Improved CF outcomes: compare significant improvements in clinical outcomes over the past 20 years; highlighting important

quality improvement projects and the impact of patient advocacy.

2. Personalized medicine in CF: describe CF genetics and the evolution of CFTR "modulators."
3. Novel CF therapies: the potential for bacteriophages to represent a personalized medicine treatment in CF.

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Richard Matthay, MD, Course Director – No conflicts of interest

Jon Koff, MD – No conflicts of interest

Gail Stanley, MD – No conflicts of interest

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.